Scientists closer to identify Parkinson’s biomarkers

Measurement of PDIA1, PDIA3, MANF and clusterin in serum using ELISA assay enables scientist to distinguish patients with Parkinson’s disease from those not affected. Credit – Shutterstock
Dec 16 2022 Posted: 12:42 GMT

 Scientists at University of Galway have identified a set of biomarkers which can distinguish patients with Parkinson’s disease from those not affected.

The study, published in the journal Molecular Neurobiology, provides a new direction for research towards a blood-based test, which combined with the current approach of clinical and neuropsychological testing would improve the diagnosis of Parkinson’s disease.

The research was led by Professor Adrienne Gorman in the School of Biological and Chemical Sciences, University of Galway. She said: “This research brings us one step closer to improving Parkinson’s disease diagnosis.” 

The study was funded by Enterprise Ireland Innovation Partnership Programme and it was conducted in collaboration with University Hospital Galway, University of Limerick and Randox Teoranta.

Parkinson’s disease is a condition that is primarily associated with the loss of motor function, such as the use of muscles and movement of limbs, due to the degeneration and death of nerves that control movement. When nerves start to die they send stress signals to the surrounding neurons and distal tissues by releasing stress-regulated proteins. 

Dr Katarzyna Mnich, the first author on the paper, said: “For that reason we were looking for markers in blood of Parkinson’s disease patients that would indicate neuronal stress.”

The research found that four stress-regulated proteins - PDIA1; PDIA3; MANF; and clusterin - enable us to distinguish Parkinson’s disease patients from those not affected by this disease. 

Dr Shirin Moghaddam, the co-author on the paper, said: “The next step is to translate our findings to a clinical diagnostic test. This requires validation of the biomarker panel in further independent cohorts to evaluate the test sensitivity and specificity for diagnosis of Parkinson’s disease.” 

Dr Mnich added: “The development of a blood-based diagnostic test would offer patients faster, cheaper and more accurate diagnosis to start their treatment sooner. And all of us on the research team would like to express our gratitude to everyone engaged in the project, especially to the people who are living with Parkinson’s disease and supported the study.”


Marketing and Communications Office


Featured Stories